



an Open Access Journal by MDPI

Breast Cancer: Future Biomarkers and Personalizing Treatment Approaches

Guest Editors:

Dr. Stefania Cocco

Istituto Nazionale Tumori IRCCS -
Fondazione G Pascale, Napoli,
Italy

Dr. Vincenzo Quagliariello

Istituto Nazionale Tumori, IRCCS,
Fondazione G. Pascale, Division
of Cardiology, Napoli, Italy

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editors

Breast cancer is a heterogeneous disease characterized by variant pathological features, disparate responses to therapeutics. During recent years, several new therapies such as PARP inhibitors, immune checkpoint inhibitors, CDK-4/6 inhibitors, and new HER-2 blocking agents, have been integrated into clinical practice, significantly improving the survival of breast cancer patients. However, many patients could early relapse due to the absence of predictive biomarkers of response and resistance to these new agents. This Special Issue welcomes the field of personalizing medicine in breast cancer, covering interdisciplinary health research, preclinical models, translational and clinical research.



mdpi.com/si/116118

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI